search
Back to results

Effects of Low-level Mechanical Vibration on Bone Density in Ambulant Children Affected by Duchenne Muscular Dystrophy

Primary Purpose

Osteoporosis, Duchenne Muscular Dystrophy

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Low-level mechanical vibrations WITH vertical sinusoidal acceleration
Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration
Sponsored by
Istituto Auxologico Italiano
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoporosis focused on measuring Duchenne Muscular Dystrophy, children, low bone mass, osteoporosis, low-level mechanical vibration, bone turnover markers

Eligibility Criteria

7 Years - 10 Years (Child)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of DMD
  • Ability to stand up and walk (some balance assistance allowed, but full weight-bearing necessary)
  • All the children must already be on glucocorticoid therapy for at least 6 months before the start of the study.

Exclusion Criteria:

  • Presence of other diseases interfering with bone density and bone turnover
  • The inability to regularly use the vibratory platform.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    mechanical intervention group

    mechanical placebo group

    Arm Description

    20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm. Intervention: to stand on the active platform (inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months.

    20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm. Intervention: to stand on the placebo platform (not inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months.

    Outcomes

    Primary Outcome Measures

    Change in bone mineral density at lumbar spine.
    Bone mineral density evaluated by DXA. Bone mineral apparent density calculated to correct for bone size (growing subjects). Z-score calculated. Measurements: baseline and 12 months.

    Secondary Outcome Measures

    Calcium
    changes in serum calcium (mg/dL)
    Phosphate
    changes in serum phosphate (mg/dL)
    Magnesium
    changes in serum magnesium (mg/dL)
    Creatinine
    changes in serum creatinine (mg/dL)
    Bone Alkaline Phosphatase
    changes in serum bone alkaline phosphatase (µg/L)
    Osteocalcin
    changes in serum osteocalcin (µg/L)
    Parathyroid Hormone
    changes in serum parathyroid hormone (ng/L)
    25-OH vitamin D
    changes in serum 25-OH vitamin D (µg/L)
    1,25(OH)2 vitamin D
    changes in serum 1,25(OH)2 vitamin D (ng/L)

    Full Information

    First Posted
    February 18, 2022
    Last Updated
    March 10, 2022
    Sponsor
    Istituto Auxologico Italiano
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05281120
    Brief Title
    Effects of Low-level Mechanical Vibration on Bone Density in Ambulant Children Affected by Duchenne Muscular Dystrophy
    Official Title
    Low-level Mechanical Vibration, Bone Density, Bone Resorption and Muscular Strength in Ambulant Children Affected by Duchenne Muscular Dystrophy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2006 (undefined)
    Primary Completion Date
    May 2007 (Actual)
    Study Completion Date
    November 2007 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Istituto Auxologico Italiano

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Duchenne muscular dystrophy (DMD) is a X-linked recessive disorder due to a mutation of the dystrophin gene (Xp21). Dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. The progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. There are no specific treatment for DMD, and the standard of care is now based on long-term corticosteroid (CS) use. The studies on bone mass in DMD are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. The aim of this study, involving 20 ambulant DMD boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant DMD children for 1 year, with RDA-adjusted dietary calcium intake and 25OH vitamin D supplementation.
    Detailed Description
    All children were instructed to have a daily intake of calcium equal to the 100% of the RDA and were supplemented with calcifediol (0.7 mcg/kg/die). The 20 boys were randomly assigned to two groups: group 1 (mechanical intervention group) = a mechanical device (a small platform designed to induce vertical, sinusoidal acceleration) was installed in the home of each boy of group 1. group 2 (placebo control group) = a placebo device was installed in the home of each boy of group 2 All boys were instructed to stand on the platform for 10 minutes each day for 12 months. Compliance was followed and stimulated through weekly telephone contacts with parents and children.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoporosis, Duchenne Muscular Dystrophy
    Keywords
    Duchenne Muscular Dystrophy, children, low bone mass, osteoporosis, low-level mechanical vibration, bone turnover markers

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    20 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    mechanical intervention group
    Arm Type
    Active Comparator
    Arm Description
    20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm. Intervention: to stand on the active platform (inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months.
    Arm Title
    mechanical placebo group
    Arm Type
    Placebo Comparator
    Arm Description
    20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm. Intervention: to stand on the placebo platform (not inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months.
    Intervention Type
    Device
    Intervention Name(s)
    Low-level mechanical vibrations WITH vertical sinusoidal acceleration
    Intervention Description
    Small platform designed to induce vertical, sinusoidal acceleration.
    Intervention Type
    Device
    Intervention Name(s)
    Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration
    Intervention Description
    Small platform designed to NOT induce vertical, sinusoidal acceleration
    Primary Outcome Measure Information:
    Title
    Change in bone mineral density at lumbar spine.
    Description
    Bone mineral density evaluated by DXA. Bone mineral apparent density calculated to correct for bone size (growing subjects). Z-score calculated. Measurements: baseline and 12 months.
    Time Frame
    baseline and 12th month
    Secondary Outcome Measure Information:
    Title
    Calcium
    Description
    changes in serum calcium (mg/dL)
    Time Frame
    baseline and 12th month
    Title
    Phosphate
    Description
    changes in serum phosphate (mg/dL)
    Time Frame
    baseline and 12th month
    Title
    Magnesium
    Description
    changes in serum magnesium (mg/dL)
    Time Frame
    baseline and 12th month
    Title
    Creatinine
    Description
    changes in serum creatinine (mg/dL)
    Time Frame
    baseline and 12th month
    Title
    Bone Alkaline Phosphatase
    Description
    changes in serum bone alkaline phosphatase (µg/L)
    Time Frame
    baseline and 12th month
    Title
    Osteocalcin
    Description
    changes in serum osteocalcin (µg/L)
    Time Frame
    baseline and 12th month
    Title
    Parathyroid Hormone
    Description
    changes in serum parathyroid hormone (ng/L)
    Time Frame
    baseline and 12th month
    Title
    25-OH vitamin D
    Description
    changes in serum 25-OH vitamin D (µg/L)
    Time Frame
    baseline and 12th month
    Title
    1,25(OH)2 vitamin D
    Description
    changes in serum 1,25(OH)2 vitamin D (ng/L)
    Time Frame
    baseline and 12th month

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    7 Years
    Maximum Age & Unit of Time
    10 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of DMD Ability to stand up and walk (some balance assistance allowed, but full weight-bearing necessary) All the children must already be on glucocorticoid therapy for at least 6 months before the start of the study. Exclusion Criteria: Presence of other diseases interfering with bone density and bone turnover The inability to regularly use the vibratory platform.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Maria Luisa Bianchi
    Organizational Affiliation
    Istituto Auxologico Italiano
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    8289083
    Citation
    Khan MA. Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci. 1993 Dec 1;120(1):8-14. doi: 10.1016/0022-510x(93)90017-s.
    Results Reference
    background
    PubMed Identifier
    2657428
    Citation
    Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15;320(24):1592-7. doi: 10.1056/NEJM198906153202405.
    Results Reference
    background
    PubMed Identifier
    10951436
    Citation
    Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, Lanzi G, Angelini C. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000 Sep;23(9):1344-7. doi: 10.1002/1097-4598(200009)23:93.0.co;2-f.
    Results Reference
    background
    PubMed Identifier
    11148511
    Citation
    Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001 Jan;138(1):45-50. doi: 10.1067/mpd.2001.109601.
    Results Reference
    background
    PubMed Identifier
    8506892
    Citation
    Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646-50. doi: 10.1016/0002-9343(93)90218-e. No abstract available.
    Results Reference
    background
    PubMed Identifier
    6866054
    Citation
    Baylink DJ. Glucocorticoid-induced osteoporosis. N Engl J Med. 1983 Aug 4;309(5):306-8. doi: 10.1056/NEJM198308043090509. No abstract available.
    Results Reference
    background
    PubMed Identifier
    685891
    Citation
    Chesney RW, Mazess RB, Rose P, Jax DK. Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child. 1978 Aug;132(8):768-72. doi: 10.1001/archpedi.1978.02120330040010.
    Results Reference
    background
    PubMed Identifier
    11059528
    Citation
    Jones G, Ponsonby AL, Smith BJ, Carmichael A. Asthma, inhaled corticosteroid use, and bone mass in prepubertal children. J Asthma. 2000;37(7):603-11. doi: 10.3109/02770900009090816.
    Results Reference
    background
    PubMed Identifier
    11041898
    Citation
    Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med. 2000 Oct 23;160(19):2917-22. doi: 10.1001/archinte.160.19.2917.
    Results Reference
    background
    PubMed Identifier
    3225269
    Citation
    Whalen RT, Carter DR, Steele CR. Influence of physical activity on the regulation of bone density. J Biomech. 1988;21(10):825-37. doi: 10.1016/0021-9290(88)90015-2.
    Results Reference
    background
    PubMed Identifier
    1805545
    Citation
    Slemenda CW, Miller JZ, Hui SL, Reister TK, Johnston CC Jr. Role of physical activity in the development of skeletal mass in children. J Bone Miner Res. 1991 Nov;6(11):1227-33. doi: 10.1002/jbmr.5650061113.
    Results Reference
    background
    PubMed Identifier
    8040762
    Citation
    Slemenda CW, Reister TK, Hui SL, Miller JZ, Christian JC, Johnston CC Jr. Influences on skeletal mineralization in children and adolescents: evidence for varying effects of sexual maturation and physical activity. J Pediatr. 1994 Aug;125(2):201-7. doi: 10.1016/s0022-3476(94)70193-8.
    Results Reference
    background
    PubMed Identifier
    9666939
    Citation
    Courteix D, Lespessailles E, Peres SL, Obert P, Germain P, Benhamou CL. Effect of physical training on bone mineral density in prepubertal girls: a comparative study between impact-loading and non-impact-loading sports. Osteoporos Int. 1998;8(2):152-8. doi: 10.1007/BF02672512.
    Results Reference
    background
    PubMed Identifier
    8609931
    Citation
    Palmieri GM, Bertorini TE, Griffin JW, Igarashi M, Karas JG. Assessment of whole body composition with dual energy x-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve. 1996 Jun;19(6):777-9. doi: 10.1002/(SICI)1097-4598(199606)19:63.0.CO;2-I. No abstract available.
    Results Reference
    background
    PubMed Identifier
    10641693
    Citation
    Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000 Jan-Feb;20(1):71-4.
    Results Reference
    background
    PubMed Identifier
    11856925
    Citation
    Aparicio LF, Jurkovic M, DeLullo J. Decreased bone density in ambulatory patients with duchenne muscular dystrophy. J Pediatr Orthop. 2002 Mar-Apr;22(2):179-81.
    Results Reference
    background
    PubMed Identifier
    12418795
    Citation
    McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, Roper H, Jardine P, Jones DH, Pike MG. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol. 2002 Oct;44(10):695-8. doi: 10.1017/s0012162201002778.
    Results Reference
    background
    PubMed Identifier
    7942156
    Citation
    Welten DC, Kemper HC, Post GB, Van Mechelen W, Twisk J, Lips P, Teule GJ. Weight-bearing activity during youth is a more important factor for peak bone mass than calcium intake. J Bone Miner Res. 1994 Jul;9(7):1089-96. doi: 10.1002/jbmr.5650090717.
    Results Reference
    background
    PubMed Identifier
    11506212
    Citation
    Vestergaard P, Glerup H, Steffensen BF, Rejnmark L, Rahbek J, Moseklide L. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med. 2001 Jul;33(4):150-5.
    Results Reference
    background
    PubMed Identifier
    11801403
    Citation
    Talim B, Malaguti C, Gnudi S, Politano L, Merlini L. Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord. 2002 Mar;12(3):294-5. doi: 10.1016/s0960-8966(01)00307-8. No abstract available.
    Results Reference
    background
    PubMed Identifier
    12897980
    Citation
    Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, Morandi L. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003 Sep;14(9):761-7. doi: 10.1007/s00198-003-1443-y. Epub 2003 Jul 29.
    Results Reference
    background
    PubMed Identifier
    12115950
    Citation
    Merlini L, Mazzone ES, Solari A, Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve. 2002 Jul;26(1):64-70. doi: 10.1002/mus.10166.
    Results Reference
    background
    PubMed Identifier
    16824816
    Citation
    Xie L, Jacobson JM, Choi ES, Busa B, Donahue LR, Miller LM, Rubin CT, Judex S. Low-level mechanical vibrations can influence bone resorption and bone formation in the growing skeleton. Bone. 2006 Nov;39(5):1059-1066. doi: 10.1016/j.bone.2006.05.012. Epub 2006 Jul 7.
    Results Reference
    background
    PubMed Identifier
    16939405
    Citation
    Gilsanz V, Wren TA, Sanchez M, Dorey F, Judex S, Rubin C. Low-level, high-frequency mechanical signals enhance musculoskeletal development of young women with low BMD. J Bone Miner Res. 2006 Sep;21(9):1464-74. doi: 10.1359/jbmr.060612.
    Results Reference
    background
    PubMed Identifier
    15040823
    Citation
    Ward K, Alsop C, Caulton J, Rubin C, Adams J, Mughal Z. Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res. 2004 Mar;19(3):360-9. doi: 10.1359/JBMR.040129. Epub 2004 Jan 27.
    Results Reference
    background

    Learn more about this trial

    Effects of Low-level Mechanical Vibration on Bone Density in Ambulant Children Affected by Duchenne Muscular Dystrophy

    We'll reach out to this number within 24 hrs